Pg. 3
What makes the Malyoth strain unique?
Bifidobacterium species, such as bifidum, not only need to be human host specific, but also infant or adult specific. Biovar is the classification used to denote whether a species is adult or infant specific; for example, biovar a (adult) or biovar b (baby). For optimal benefit, the appropriate biovar of bifidobacteria should be administered. The Malyoth strain of B. bifidum – biovar a is an appropriate supplement for adults and for children
who have been weaned from breast milk. This strain has been used successfully in liver detoxification studies. 5,53,54
Bifidobacterium bifidum possesses the following positive characteristics:
• Helps in the production of B vitamins in the gastrointestinal (GI) tract. 5,7,56,66
• By producing acetic acid and lactic acids, it lowers the pH of the intestines thus inhibiting undesirable bacteria, acting as an antimicrobial agent. 5,7
• Helps to inhibit the colonization of the intestines by invading pathogens with which it competes for nutrients and attachment sites. 5,7,8
• Helps in liver function and detoxification. 5,53,54

Aging lowers gastric acidity and allows more competitive microorganisms to reach the large intestine, resulting in a loss of valuable bifidobacteria. The spaces left vacant on the wall of the large intestine by the lack of bifidobacteria are gradually taken over by undesirable bacteria. Noxious bacteria form substances that cause putrefaction and contribute to intestinal problems.

Healthy Trinity oil matrix capsules are commonly used as a nutritional adjunct to replenish normally occurring beneficial organisms in the gastrointestinal tract. This is vital, particularly during and following antibiotics, corticosteroids (cortisone), chemotherapy, diarrhea, and chronic yeast or bacterial overgrowth. Ongoing stress also negatively alters the delicate balance of beneficial bacteria. Japanese research indicates that Bifidobacteria is the most important beneficial bacteria for human health.

In vitro studies have demonstrated the following effects of Bifidobacteria bifidum:
• Produce strong organic acids (lactic, formic, acetic) that inhibit the growth of undesirable microorganisms. 5,7,66
• May suppress harmful bacteria that may ultimately lead to aging and geriatric diseases. 5,7,8,50
• Lower the fecal pH, which in turn decreases ammonia and frees phenols in the blood. 5,7,53,54

What makes the LB-51 strain unique?
L. bulgaricus strain LB-51 has been studied in Bulgaria for more than 30 years by leading scientists. Its unique properties are well documented.
L. bulgaricus in Healthy Trinity travels along with food as it is being digested. It may take up to two weeks to pass through the digestive tract. Along the way, L. bulgaricus naturally aids digestion and helps contain unfriendly organisms. In vitro studies have demonstrated benefits of certain strains of L. bulgaricus:
• May help to promote regularity by stimulating peristaltic action. It may help alleviate the need for laxatives and help maintain the natural electrolyte balance, particularly with aging and a less active lifestyle. 3,64
• Produce lactase, which aids in the natural digestion of lactose (milk sugar) and may be effective with lactose intolerance. Yogurt contains L. bulgaricus, which provides 30 times the lactase activity of sweet acidophilus milk. 28,39,44,65,78
• Help the body digest carbohydrates, producing lactic acid, which creates a hostile environment for harmful bacteria. Lactic acid may also improve the digestibility of casein. 6,14,24,61,75
• Naturally help in the digestion of protein. Mild proteolytic activity of these bacteria may aid the digestion of nutrients, particularly milk protein. The protein in yogurt, which has been cultured by L. bulgaricus, becomes twice as digestible as regular milk protein. It has been shown to help produce small peptides and free-form amino acids which are readily absorbed by the body. The production of free-form amino acids also assists mineral absorption. 14,69,75
• The lactic acid produced by L. bulgaricus may increase the bioavailability of minerals, especially calcium. The absorption is doubly important in lactose-intolerant individuals who may experience a deficiency of dietary calcium. 14,20,28,69,74,75
• Help discourage undesirable microorganisms in other ways. In large numbers, it will out-compete hostile microorganisms searching for nutrients. 48,60
• Through its production of hydrogen peroxide, and of lactic acid, creating a more acidic environment, L. bulgaricus LB-51 also acts as an antimicrobial, which is inhibitory to many undesirable microorganisms and yeasts.* 21,24,61 In an in vitro study, L. delbrueckii subsp. bulgaricus LB-51 strain exhibited antimicrobial activity against H. pylori. 67

*Please see article, "Longevity and the Importance of L. bulgaricus Supplementation."

Directions for Use
For adults and children over 8 years of age. Take 1 or more capsules daily. Healthy Trinity oil matrix capsules are formulated to be taken with meals to enhance digestion but may be taken at any time.

Note: Healthy Trinity capsule size (00) may not be suitable for young children, although contents of capsule are nontoxic and safe for children. Those who have difficulty swallowing capsules, such as young children, may find Natren’s powdered probiotic formulas more suitable.

Storage
Store at 2°C to 8°C.
Keep refrigerated (do not freeze) to maintain guaranteed potency. Do not expose to moisture, heat or direct sunlight.

Potency Guarantee
Each capsule is guaranteed to supply a minimum of:
• 5 billion cfu L. acidophilus, NAS super strain
• 20 billion cfu B. bifidum, Malyoth super strain
• 5 billion cfu L. bulgaricus, LB-51 super strain
through the printed expiration date if recommended storage conditions are maintained.


FOR FURTHER INFORMATION CALL:

1-866-462-8736


References

1. Adams, M. R., and Hall, C. J., Growth inhibition of food borne pathogens by lactic and acetic acids and their mixtures., Int. J. Food Sci. Technol., 1988; 23: 287-292.
2. Akalin, A. S., Gonc, S., and Duzel, S., Influence of yogurt and acidophilus yogurt on serum cholesterol levels in mice, J. Dairy Sci., 1997; 80 (11) 2721-2725.
3. Alm, L., The therapeutic effects of various cultures-an overview. In: Therapeutic properties of fermented milks, Ed: R.K. Robinson, Elsevier Science Publishers Ltd. London, 1991, pp45-64.
4. Anderson, J. W., and Gilliland, S. E., Effect of fermented milk (yogurt) containing Lactobacillus acidophilus L1 on serum cholesterol in hypercholesterolemic humans, J. Am. Coll. Nutr. 1999; 18(1):43-50.
5. Arunachalam, K. D., Role of bifidobacteria in nutrition, medicine and technology, Nutr. Res., 1999; 19(10): 1559-1597.
6. Axelsson, L., Lactic acid bacteria: Classification and physiology. In: Lactic Acid Bacteria: Microbiology and Functional Aspects, Eds: S. Salminen, A. von Wright, 2nd Ed., 1998; pp 1-72.
7. Ballongue, J. Bifidobacteria and probiotic action, In: Lactic Acid Bacteria, Salminen, S., von Wright, A., (Eds.), Marcel Dekkar, Inc., New York, 1998, 519-587.
8. Bernet, M. F., Brassart, D., Neeser, J. R., and Servin, A. L., Adhesion of human bifidobacterial strains to cultured human intestinal epithelial cells and inhibition of enteropathogen-cell interactions, Appl. Environ. Microbiol., 1993; 59: 4121-4128.
9. Bernet, M. F., Brassart, D., Neeser, J. R., and Servin, A. L., Lactobacillus acidophilus LA 1 binds to cultured human intestinal cell lines and inhibits cell attachment and cell invasion by enterovirulent bacteria, Gut, 1994; 35: 483-489.
10. Bernet-Camard., M. F., Lievin, V., Brassart, D., Neeser, J. R., Servin, A., and Hudault, S., The human Lactobacillus acidophilus Strain LA1 secretes a nonbacteriocin antibacterial substance(s) active in vitro and in vivo, Appl. Environ. Microbiol., 1997; 63(7): 2747-2753.
11. Bhatia, S., Kochar, N., Abraham, P., Nair, N., and Mehta, A., Lactobacillus acidophilus inhibits growth of Campylobacter pylori in vitro, J. Clin. Microbiol. 1989; 27(10): 2328-2330.
12. Bogovic-Matijasic, B., Rogelj, I., Nes, I. F., and Holo, H., Isolation and characterisation of two bacteriocins of Lactobacillus acidophilus LF221, Appl. Microbiol. Biotechnol., 1998; 49(5): 606-612.
13. Boris, S., Suarez, J. E., Vazquez, F., and Barbes, C., Adherence of human vaginal Lactobacilli to vaginal epithelial cells and interaction with uropathogens, Infect. Immun., 1998; 66(5): 1985-1989.
14. Chebbi, N.B., Chander, H., Ranganathan, B., Casein degredation and amino acid liberation in milk by two highly proteolytic strains of lactic acid bacteria, Acta Microbiol. Pol., 1977; 26(3):281-284.
15. Clemens, R., Friendly bacteria – a functional food, Food Technology, 2001; 55(1): 27.
16. Coconnier, M. H., Bernet, M. F., Chauviere, G., and Servin, A. L., Adhering heat-killed human Lactobacillus acidophilus, strain LB, inhibits the process of pathogenicity of diarrhoeagenic bacteria in cultured human intestinal cells, J. Diarrhoeal Dis. Res., 1993b; 11: 235-242.
17. Coconnier, M. H., Bernet, M. F., Kerneis, S., Chauviere, G., Fourniat, J., and Servin, A. L., Inhibition of adhesion of enteroinvasive pathogens to human intestinal Caco-2 cells by Lactobacillus acidophilus strain LB decreases bacterial invasion, FEMS Microbiol. Lett., 1993a; 110: 299-305.
18. Coconnier, M. H., Lievin, V., Bernet-Camard., M. F., Hudault, S., and Servin, A., Antibacterial effect of the adhering human Lactobacillus acidophilus Strain LB, Antimicrob. Agents Chemother., 1997; 41(5): 1046-1052. partial purification of bulgarican from L. bulgaricus, Cultured Dairy Products Journal, 1983; 15-19.

 19. Collins, E. B., and Hardt, P., Inhibition of Candida albicans by Lactobacillus acidophilus, J. Dairy Sci., 1980; 63(5): 830-832.
20. Cummings, J. H., and MacFarlane, G. T., Role of intestinal bacteria in nutrient metabolism, J. P. E. N. 1997; 21(6):357-365.
21. Dahiya, R. S., and Speck, M. L., Hydrogen peroxide formation by lactobacilli and its effect on Staphylococcus aureus, J. Dairy Sci., 1968; 51(10): 1068-1072.
22. Danielson, A. D., Peo, E. R. J., Shahani, K. M., Lewis, A. J., Whalen, P. J., and Amer, M. A., Anticholesterolemic property of Lactobacillus acidophilus yogurt fed to mature boars, J. Animal Sci., 1989; 67: 966-974.
23. De Rodas, B. Z., Gilliland, S. E., and Maxwell, C. V., Hypocholesterolemic action of Lactobacillus acidophilus ATCC 43121 and calcium in swine with hypercholesterolemia induced by diet, J. Dairy Sci., 1996; 79: 2121-2128.
24. De Vuyst, L., and Vandamme, E. J., Antimicrobial potential of lactic acid bacteria. In: Bacteriocins of lactic acid bacteria, De Vuyst, L., and Vandamme E J, Eds., Chapman and Hall, London, 1994, 91-142.
25. Dembele, T., Obdrzalek. V., and Votava, M., Inhibition of bacterial pathogens by lactobacilli, Zentralbl. Bakteriol. 1998;288(3):395-401.
26. Fitzsimmons, N., and Berry, D. R., Inhibition of Candida albicans by Lactobacillus acidophilus: evidence for the involvement of a peroxidase system, Microbios, 1994; 80: 125-133.
27. Fukushima, M., and Nakano, M., Effects of a mixture of organisms, Lactobacillus acidophilus or Streptococcus faecalis on cholesterol metabolism in rats fed on a fat- and cholesterol-enriched diet, Br. J. Nutr., 1996; 76: 857-867.
28. Gilliland, S. E., and Kim, H. S., Effect of viable starter culture bacteria in yogurt on lactose utilization in humans, J. Dairy Sci., 1984; 67: 1-6.
29. Gilliland, S. E., and Walker, D. K., Factors to consider when selecting a culture of Lactobacillus acidophilus as a dietary adjunct to produce a hypocholesterolemic effect in humans, J. Dairy Sci., 1990; 73: 905-911.
30. Gilliland, S. E., Nelson, C. R., and Maxwell, C., Assimilation of cholesterol by Lactobacillus acidophilus, Appl. Environ. Microbiol., 1985; 49: 377-381.
31. Goldin, B. R., Swenson, L., Dwyer, J., Sexton, M., and Gorbach, S. L., Effect of diet and Lactobacillus acidophilus supplements on human fecal bacterial enzymes, J. Natl. Cancer Inst., 1980; 64: 255-261.
32. Goldin, B.R., and Gorbach, S. L., Alterations in fecal microflora enzymes related to diet, age, lactobacillus supplements, and dimethylhydrazine, Cancer, 1977; 40: 2421-2426.
33. Gorbach, S., Lactic acid bacteria and human health, Ann. Of Med., 1990; 22: 37-41.
34. Hilton, E., Isenberg, H. D., Alperstein, P., France, K., and Borenstein, M. T., Ingestion of yogurt containing Lactobacillus acidophilus as prophylaxis for Candidal vaginitis, Ann. Intern. Med., 1992; 116: 353-357.
35. Hood, S.K., and Zottola, E.A., Electron microscopic study of the adherence properties of Lactobacillus acidophilus. J. Food Sci., 1987; 52:791-805.
36. Kim, H. S., and Gilliland, S. E., Lactobacillus acidophilus as a dietary adjunct for milk to aid lactose digestion in humans, J. Dairy Sci., 1983; 66: 959-966.
37. Klaenhammer, T. R., Genetics of bacteriocins produced by lactic acid bacteria, FEMS Microbiol. Rev., 1993; 12(1-3): 39-85.
38. Klebanoff, S. J., Hillier, S. L., Eschenbach, D. A., and Waltersdorph, A. M., Control of the microbial flora of the vagina by H2O2-generating lactobacilli, J. Infect. Dis., 1991; 164(1): 94-100.
39. Kolars, J. C., Levitt, M. D., Aouji, M., and Savaiano, D. A., Yogurt - an autodigesting source of lactose, N. Eng. J. Med., 1984; 310(1): 1-3.
40. Letter on file.
41. Lidbeck, A., Nord, C. E., Gustafsson, J. A., and Rafter, J., Lactobacilli, anticarcinogenic activities and human intestinal microflora, Eur. J. Cancer Prev., 1992; 1: 341-353.
42. Lin, M.-Y., Savaiano, D., and Harlander, S., Influence of nonfermented dairy products containing bacterial starter cultures on lactose maldigestion in humans, J. Dairy Sci., 1991; 74: 87-95.
43. Link-Amster, H., Rochat, F., Saudan, K. Y., Mignot, O., and Aeschlimann, J. M., Modulation of a specific humoral immune response and changes in intestinal flora mediated through fermented milk intake, FEMS Immunol. Med. Micro., 1994; 10: 55-64.
44. Martini, M. C., Lerebours, E. C., Lin, W.-J., Harlander, S. K., Berrada, N. M., Antoine, J. M., and Savaiano, D. A., Strains and species of lactic acid bacteria in fermented milks (yogurts): effect on in vivo lactose digestion, Am. J. Clin. Nutr., 1991; 54: 1041-1046.
45. McDonough, F. E., Wong, N. P., Hitchins, A., and Bodwell, C. E., Alleviation of lactose malabsorption from sweet acidophilus milk, Am. J. Clin. Nutr., 1987; 42: 345-346.
46. Metts, J., Lactobacillus acidophilus strain NAS (H2O2 positive) in reduction of recurrent Candidal vulvovaginitis, 2001; (ms submitted).
47. Midolo, P. D., Lambert, J. R., Hull, R., Luo, F., and Grayson, M. L., In vitro inhibition of Helicobacter pylori NCTC 11637 by organic acids and lactic acid bacteria, J. Appl. Bacteriol., 1995; 79(4):, 475-479.
48. Mikelsaar, M., Mämdar. R., Sepp, E., Lactic acid microflora in the human micobial ecosystem and its development, In: Lactic acid bacteria: microbiology and functional aspects, Eds: S. Salminen, A. von Wright, 2nd Ed, 1998; pp 279-342.
49. Mital, B. K., and Garg, S. K., Anticarcinogenic, hypocholesterolemic, and antagonistic activities of Lactobacillus acidophilus, Critical Rev. Microbiol., 1995; 21(3): 174-214.
50. Mitsuoka, T., Intestinal flora and aging. Nutrition Rev. 1992; 50(12): 438-446.
51. Montes, R. G., Bayless, T. M., Saavedra, J. M., and Perman, J. A., Effect of milks inoculated with Lactobacillus acidophilus or a yogurt starter culture in lactose-maldigesting children, J. Dairy Sci., 1995; 78: 1657-1664.
52. Mustapha, A., Jiang, T., and Savaiano, D. A., Improvement of lactose digestion by humans following ingestion of unfermented acidophilus milk: influence of bile sensitivity, lactose transport, and acid tolerance of Lactobacillus acidophilus, J. Dairy Sci. 1997; 80(8):1537-1545.
53. Müting, D., Eschrich, W., and Mayer, J. B., The effect of Bifidobacterium bifidum on intestinal bacterial flora and toxic protein metabolites in chronic liver disease, Am. J. Proctol., 1968; 19: 336-342.
54. Müting, D., Leimbeck, R., Flasshoff, H., and Rusch, V., Bifidobacterium bifidum administration in humans: a controlled clinical study in liver cirrhosis, Microecology and Therapy, 1986; 16: 271-272.
55. Nader de Macias, M. E., Apella, M. C., Romero, N. C., Gonzalez, S. N., and Oliver, G., Inhibition of Shigella sonnei by Lactobacillus casei and Lactobacillus acidophilus, J. Appl. Bacteriol., 1992; 73: 407-411.
56. Naidu, AS, WR Bidlack, RA Clemens. Probiotic spectra of lactic acid bacteria (LAB). CRC Critical Rev. Fd. Sci. Nutr., 2000; 39(1):13-126.
57. National Nutritional Foods Association, NNFA Probiotic Labeling Standard March, 1989 (Probiotics: Acidophilus-Like Products).
58. Natural Products Quality Assurance Alliance, Document of Quality and Safety Standards, 1995.
59. Nes, I. F., Diep, D. B., Havarstein, L. S., Bruberg, M. B., Eijsink, V., and Holo, H., Biosynthesis of bacteriocins in lactic acid bacteria, Antonie Van Leewenhoek, 1996; 70(2-4): 113-128.
60. Ouwehand, A. C., Isolauri, E., Kirjavainen, P. V., Tolkko, S., and Salminen, S. J., The mucus binding of Bifidobacterium lactis Bb12 is enhanced in the presence of Lactobbacillus GG and Lact. delblrueckii supsp. Bulgaricus, Lett. Appl. Microbiol. 2000;30(1):10-3.
61. Ouwehand, A.C. Antimicrobial components from lactic acid bacteria. In: Lactic acid bacteria: microbiology and functional aspects, Eds: S. Salminen, A. von Wright, 2nd Ed; Marcel Dekker, New York, 1998, pp139-160.
62. Perdigon, G., de Macias, M. E., Alvarez, S., Oliver, G., and de Ruiz Holdado, A. P., Systemic augmentation of the immune response in mice by feeding fermented milks with Lactobacillus casei and Lactobacillus acidophilus, Immunology, 1988; 63(1): 17-23.
63. Perdigon, G., Nader de Macias, M. E., Alvarez, S., Oliver, G., and Pesce de Ruiz Holgado, A. A., Enhancement of immune response in mice fed with Streptococcus thermophilus and Lactobacillus acidophilus, J. Dairy Sci., 1987; 70: 919-926.
64. Porkka, L., Salminen, E., and Salminen, S., The effects of lactulose-sweeted yoghurt on the rate of gastric emptying and intestinal transit in healthy human volunteers, Z. Ernahrungswiss, 1988; 27(3): 150-4.
65. Rao, M.V., and Dutta, S.M., Lactase activity of microorganisms, Folia Microbiol. (Praha), 1978; 23(3):210-215.
66. Rasic, J. Lj., and Kurmann, J. A., Bifidobacteria and their role, Birkhauser Velag, Basel, 1983.
67. Rasic, J., Klem, I., Jovanovic, D., and Ac, M., Antimicrobial effect of Lactobacillus acidophilus and Lactobacillus delbrueckii subsp. bulgaricus against Helicobacter pylori in vitro, Arch. Gastroenterohepatol. 1995; 14(4): 158-160.
68. Rasic, J.Lj. (1989-1993) Laboratory studies.
69. Rasic, J.Lj., and Kurmann, J. A., Yoghurt: Scientific grounds, technology, manufacture and preparations, Staempfli + Cie AG, Berne: 1978.
70. Reddy, G. V., Shahani, K. M., Friend, B. A., and Chandan, R. C., Natural Antibiotic Activity of Lactobacillus Acidophilus and Bulgaricus. III. Production andpartial purification of bulgarican from L. Bulgaricus, Cultured Dairy Products Journal, 1983; 15-19
71. Reid, G., Tieszer, C., and Lam, D., Influence of lactobacilli on the adhesion of Staphylococcus aureus and Candida albicans to fibers and epithelial cells, J. Ind. Microbiol., 1995; 15(3): 248-253.
72. Shahani, K. M., Vakil, J. R., and Kilara, A., Natural Antibiotic Activity of Lactobacillus Acidophilus and Bulgaricus. II. Isolation of Acidophilin from L. acidophilus, Cultured Dairy Products Journal, 1977; 12(2): 8-11.
73. Siuta-Cruce, P., and Goulet, J., Improving probiotic survival rates, Food Technology, 2001; 55(10):36-42.
74. Smith, T. M., Kolars, J. C., Savaiano, D. A., and Levitt, M. D., Absorption of calcium from milk and yogurt, Am. J. Clin. Nutr., 1985; 42: 1197-1200.
75. Tsakalidou, E., Anastasiou, R., Vandenberge, I., van Beeumen, J., Kalantzopoulos, G., Cell-wall bound proteinase of Lactobacillus delbrueckii subsp. Lactis ACA-DC 178: characterization and specificity for beta-casein, Appl. Environ. Microbiol. 1999; 65(5):2035-2040.
76. Velraeds, M. M., van der Mei, H. C., Reid, G., and Busscher, H. J., Inhibition of initial adhesion of uropathogenic Enterococcus faecalis by biosurfactants from Lactobacillus isolates, Appl. Environ. Microbiol., 1996; 62(6): 1958-1963.
77. Velraeds, M. M., van der Mei, H. C., Reid, G., and Busscher, H. J., Inhibition of initial adhesion of uropathogenic Enterococcus faecalis to solid substrata by an adsorbed biosurfactant layer from Lactobacillus acidophilus, Urology, 1997; 49(5): 790-794.
78. Vesa, T.H., Marteau, P., Zidi, S., Briet, F., Pochart, P., Rambaud, J.C., Digestion and tolerance of lactose from yoghurt and different semi-solid fermented dairy products containing Lactobacillus acidophilus and bifidobacteria in lactose maldigesters—is bacterial lactase important? Eur. J. Clin. Nutr., 1996;50(11):730-733.
79. Wagner, R. D., Pierson, C., Warner, T., Dohnalek, M., Farmer, J., Roberts, L., Hilty, M., and Balish, E., Biotherapeutic effects of probiotic bacteria on Candidiasis in immunodeficient mice, Infect. Immun., 1997; 65(10): 4165-4172.
80. Williams, A.B., Chang, Y., Tashima, K., Burgess, J., Danvers, K., Evaluation of two self-care treatments for prevention of vaginal candidiasis in women with Human Immunodeficiency Virus infection, J. Assoc Nurses AIDS Care, 2001; 12(4): 51-7.
 
Specials Your Health Infants Beauty Women Men Animals Books Contact Us Store Locator
HACKER SAFE certified sites prevent over 99.9% of hacker crime.
The symbols ™ or ® denote trademarks or registered trademarks of Natren Inc. and Healthy Friends Inc.. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease. Copyright © 2007 Natren Inc. All rights reserved.